Intraductal papillary and mucinous tumors of the pancreas: accuracy of preoperative computed tomography, endoscopic retrograde pancreatography and endoscopic ultrasonography, and long-term outcome in a large surgical series

Cellier, Christophe; Cuillerier, Emmanuel; Palazzo, Laurent; Rickaert, Fabienne; Fléjou, Jean‐François; Napoléon, Bertrand; Gansbeke, Daniel Van; Bély, N; Ponsot, Philippe; Partensky, Christian; Cugnenc, Paul-Henri; Barbier, J; Devière, Jacques; Cremer, Michel

doi:10.1016/s0016-5107(98)70297-4

Cited by 213 publications

(129 citation statements)

References 26 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Three of the 4 unresectable patients in this series had values higher than 2000 U/mL. Cellier and colleagues 11 found invasive carcinoma in 43% of their patients and carcinoma in situ in 21%, with significantly poorer prognosis for patients with invasive carcinoma. The overall actuarial 3-year survival for patients with IPMTs was 83% in their series, whereas the overall recurrence-free 3-year survival was only 21% among patients with invasive disease.…”

Section: Intraductal Mucin-hypersecreting Neoplasmsmentioning

confidence: 50%

See 1 more Smart Citation

Mucinous Tumors of the Exocrine Pancreas

Eloubeidi

Hawes

2000

Cancer Control

View full text Add to dashboard Cite

show abstract

Section: Intraductal Mucin-hypersecreting Neoplasmsmentioning

confidence: 50%

“…Cellier and colleagues 11 reported on the role of EUS in assessing tumor extension and invasion in patients with IPMTs (Fig 2). They demonstrated that the sensitivity and specificity of EUS for invasive malignancy were 78% and 75%, respectively.…”

Section: Intraductal Mucin-hypersecreting Neoplasmsmentioning

confidence: 99%

Mucinous Tumors of the Exocrine Pancreas

Eloubeidi

Hawes

2000

Cancer Control

View full text Add to dashboard Cite

show abstract

“…Sin embargo la presencia de compromiso multifocal o difuso a lo largo del conducto se observa en 33% de los pacientes 15 . Presencia de atipia, cáncer in situ o cáncer invasor se observa en 60% de las piezas resecadas 12 , variando este porcentaje de acuerdo a las series entre 52% y 88% 16,17 .…”

Section: Tumor Intraductal Papilar Mucinoso (Tipm)unclassified

Tumores quísticos del páncreas

et al. 2008

View full text Add to dashboard Cite

Cystic tumors of the pancreas (Rev Méd Chile 2008; 136: 1188-96L os tumores de la glándula pancreática se caracterizan en general por su diagnóstico tardío y mal pronóstico. El tumor pancreático más común es el adenocarcinoma de los conductos y su sobrevida promedio no sobrepasa 5% a 5 años [1][2][3][4] .Durante los últimos años, ha sido posible el diagnóstico de una mayor cantidad de lesiones denominadas «incidentalomas», de las cuales las lesiones quísticas pancreáticas representan una importante proporción.Este fenómeno ha sido claramente descrito por el grupo del Massachussets General Hospital, quienes comunican cómo ellos han duplicado las resecciones pancreáticas efectuadas por tumores quísticos durante la última década 5 . Igual tendencia se observa en el reporte efectuado por Allen, de la experiencia del Memorial Sloan Kettering Center, quienes muestran un aumento en los casos evaluados, con 5 casos en 1995 comparado con 117 en 2004 6 .Debido al aumento en su diagnóstico y a las dificultades que su identificación ofrece, hemos querido analizar las principales características clí-nicas, radiológicas y patológicas de las lesiones más frecuentes del páncreas, con énfasis en todas aquellas diferentes al adenocarcinoma ductal. Tumor intraductal papilar mucinoso (TIPM).Constituye entre 20% y 30% de los tumores quísticos pancreáticos. Se caracteriza por desarrollarse a partir del epitelio del conducto pancreático principal o de alguna de sus ramas y por presentar secreción mucinosa espesa que se asocia a dilatación tanto del conducto como a la formación de quistes 7,8 .Esta lesión fue primeramente descrita en Japón en 1982 por Ohhashi 9 . El término TIPM fue dado recién en 1996 y 1997 por la Organización Mundial de la Salud y el Instituto de Patología de las Fuerzas Armadas, respectivamente 10,11 .Afecta con igual frecuencia a ambos sexos y mayoritariamente a pacientes en la sexta y séptima década 12 .

show abstract

“…There have been increasing numbers being reported from Japan, the US, and Europe because of rising incidence or perhaps better imaging techniques and awareness of the disease (2)(3)(4). Its clinical features, in its classic form, are characterized by diffuse dilation of the main pancreatic duct, or the grapelike clusters of contrast material on ERP in the branch duct type.…”

Section: Endosonography For Differentiating Benign From Malignant Intmentioning

confidence: 99%

“…The disease seems to progress slowly, as suggested by the time intervals reported between onset of symptoms and time of diagnosis (2,6). IPMTs are clearly premalignant neoplasms, with up to 46% of patients having invasive carcinoma at the time of surgery (2,4,6). The tumor has a high prevalence of K-RAS mutations that directly correlate with the degree of neoplasia, ranging from low in low grade dysplasia to the same high levels found in pancreatic adenocarcinoma in cases of frank carcinoma (6).…”

Section: Endosonography For Differentiating Benign From Malignant Intmentioning

confidence: 99%

Endosonography for differentiating benign from malignant intraductal mucinous tumors of the pancreas: Is the Jury Out?

Waxman¹

2001

The American Journal of Gastroenterology

View full text Add to dashboard Cite

Intraductal papillary and mucinous tumors of the pancreas: accuracy of preoperative computed tomography, endoscopic retrograde pancreatography and endoscopic ultrasonography, and long-term outcome in a large surgical series

Cited by 213 publications

References 26 publications

Mucinous Tumors of the Exocrine Pancreas

Mucinous Tumors of the Exocrine Pancreas

Tumores quísticos del páncreas

Endosonography for differentiating benign from malignant intraductal mucinous tumors of the pancreas: Is the Jury Out?

Contact Info

Product

Resources

About